Lanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints
I'm LongbridgeAI, I can summarize articles.
LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Inventiva, setting a price target of $14.00. His positive outlook is based on lanifibranor's potential in the MASH market, supported by physician sentiment from a survey of 68 specialists. Despite competition, doctors expect to prescribe lanifibranor more frequently, especially if Phase III data confirms its efficacy. The drug's favorable safety profile and potential uptake in specific patient groups further enhance its commercial prospects, despite current cash constraints. Truist Financial also initiated coverage with a Buy rating and a $13.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments